CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)
Norbert Schmitz(University Hospital Münster), Michael Pfreundschuh(Saarland University), Markus Loeffler(Leipzig University), Eva Cavallin‐Ståhl(Lund University), Ulrich Kaiser(University of Applied Sciences Landshut), Samira Zeynalova(Leipzig University), Max Wolf(Peter MacCallum Cancer Centre), Bertram Glaß(Helios Hospital Berlin-Buch), Lorenz Trümper(University of Göttingen), Mathias Haenel(Klinikum Chemnitz)
Cited by 6
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes
|Nature Communications|2018|1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k